A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer

• Status: Completed
• Trial end date: 1969-12-31

Summary

To evaluate whether two weekly concurrent chemoradiotherapy regimens offer any advantage over concurrent chemoradiotherapy regimens with Cisplatin, Vindesine, Mitomycin for unresectable stage III NSCLC.

• Phase: Phase 3

Details

• Lead Sponsor: West Japan Thoracic Oncology Group
• Treatments: Albumin-Bound Paclitaxel; Camptothecin; Carboplatin; Cisplatin; Irinotecan; Mitomycin; Mitomycins; Paclitaxel; Vindesine